Research Progress on Tumor Treatment Strategies Targeting TGF-β
10.3971/j.issn.1000-8578.2025.24.0735
- VernacularTitle:靶向TGF-β的肿瘤治疗策略研究进展
- Author:
Jian ZHANG
1
;
Binyue LYU
2
;
Xiao ZHAO
3
Author Information
1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
2. Department of Infectious Disease, The First Hospital of Tsinghua University, Beijing 100020, China.
3. Department of Oncology, General Hospital of Chinese PLA, Fifth Medical Center, Beijing 100080, China.
- Publication Type:REVIEWS
- Keywords:
TGF-β;
Cancer;
Therapeutic strategies;
Tumor immune environment
- From:
Cancer Research on Prevention and Treatment
2025;52(1):74-78
- CountryChina
- Language:Chinese
-
Abstract:
The TGF-β signaling pathway affects various biological processes of cancers, including proliferation, invasion, metastasis, angiogenesis, and immune escape. Currently, multiple drugs targeting this pathway are in clinical trial stage, which involve three aspects of TGF-β, namely, production, activation, and signal transduction. Based on current evidence, the therapeutic effect of TGF-β monotherapy on advanced solid tumors is limited. Combination therapies that show promising results include combination with PD-1 antibodies, and combination with radiotherapy and chemotherapy. New combination therapies, such as CAR-T therapy modified with TGF-βRII, are also emerging in clinical research. This article systematically reviews the therapeutic strategies targeting TGF-β to provide research basis and ideas for the development of drugs targeting the TGF-β pathway.
